BioMeetingpoint at the Biotechnica

The Biotechnology Thematic Group (BioTG) of the IRC Network together with other European partners are organising again the BioMeetingpoint for companies, R&D organisations and stakeholders to hold bilateral meetings at Biotechnica Hannover, Europe's leading biotechnology trade fair, which will take place in Hannover, Germany 9 - 11 October 2007.

Since 1985 Biotechnica Hannover has been the most important trade show in Europe for biotechnology. For the BioMeetingpoint a catalogue of company profiles and technology offers and requests will be available electronically and will allow participating companies and organisations to organise their individual meetings in advance.

The BioMeetingpoint functions as an "interface between research and the private sector" allowing new technologies, processes, patents and licenses to be offered and experience in financing, production, marketing and distribution to be requested, thus bringing compatible partners together.

The BioMeetingpoint is the ideal environment for:

  • Enterprises offering and/or using innovative technologies.
  • Enterprises that are looking for expertise and know-how in the areas of production, marketing and distribution or wish to provide this knowledge to others.
  • Scientists and research institutes offering application-oriented research results.
  • Start-ups.
  • Investors.

They will have the opportunity to get to know selected partners during individual discussions, which aim to pave the way for future co-operations.

For further information, please visit:
http://www.biomeetingpoint.org

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...